Drug Trial Radar · NCT06243458
RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms
Last checked: Nov 19, 2026Latest source record: May 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
41
Actual
Start
Sep 10, 2024
Primary completion
May 2026
Study completion May 2027
Sponsor
- Lead sponsor
- GCP-Service International West GmbHIndustry
- Sponsor type
- Industry
- Collaborators
- Universitätsklinikum Leipzig; Saint-Louis Hospital, Paris, France; University of Florence; University of Salamanca; Medical University of Warsaw; Ryvu Therapeutics SA; European Myelodysplastic Neoplasms Cooperative Group
- First posted
- Feb 6, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate orally administered RVU120, a novel small molecule Cyclin-dependent Kinase (CDK) 8/19 inhibitor, in terms of erythroid hematologic improvement (HI-E) and safety in participants with lower-risk myelodysplastic syndrome (MDS). Responding patients are eligible to continue treatment until loss of response/disease progression.
Conditions
- Low Risk Myelodysplastic Syndromes
Interventions
RVU120 (SEL120)Drug
RVU120 will be taken orally every other day (q.o.d). in a 21-day treatment cycle. Doses of RVU120 will be administered from day 1 to day 13 (total of 7 doses per cycle).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Erythroid Response (HI-E) Rate of Participants after Treatment with RVU120 (dose of 150 mg)Time frame: Response Assessment measured after 8 full Cycles of RVU120 administration. Each cycle is 21 days.
Locations
25 sites in 5 countries. Site status is shown where the registry gives one.
CHU Grenoble Alpes - Hôpital Michallon
Grenoble, France
CHU de Nice - Hôpital l'Archet 1
Nice, France
Hôpital Saint-Louis, Service d'Hématologie Séniors
Paris, France
CHU de Bordeaux - Centre François Magendie - Groupe Hospitalier Sud
Pessac, France
CHU de Toulouse - Institut Universitaire du Cancer de Toulouse - Oncopole
Toulouse, France
Marien Hospital Düsseldorf
Düsseldorf, Germany
Universität Leipzig, Med. Fak., Klinik und Poliklinik für Hämatologie, Zelltherapie, Hämostaseologie und Infektiologie
Leipzig, Germany
Universitätsklinikum Münster (UKM)
Münster, Germany
AOU delle Marche
Ancona, Italy
AOU Consorziale Policlinico, Università degli Studi Aldo Moro
Bari, Italy
Candiolo Cancer Institute, IRCCS Fondazione del Piemonte per l'Oncologia
Candiolo, Italy
AOU Careggi
Florence, Italy
IRCCS Humanitas Research Hospital
Milan, Italy
Grande Ospedale Metropolitano Bianchi-Melacrino-Morelli
Reggio Calabria, Italy
Samodzielny Publiczny Szpital Kliniczny im.Andrzeja Mielęckiego Śląskiego Uniwersytetu Medycznego w Katowicach
Katowice, Poland
Pratia Hematologia Sp. z o. o. , Pratia Onkologia Katowice
Katowice, Poland
Wojewódzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M.Kopernika w Łodzi
Lodz, Poland
MTZ Clinical Research powered by Pratia
Warsaw, Poland
Uniwersytecki Szpital Kliniczny im.Jana Mikulacza-Radeckiego
Wroclaw, Poland
Hematology Department Vall d'Hebron Institute of Oncology (VHIO)
Barcelona, Spain
Hospital Universitario de León
León, Spain
Hospital Universitario La Paz
Madrid, Spain
Navarra university clinic
Pamplona, Spain
Complejo Asistencial Universitario de Salamanca
Salamanca, Spain
Hospital Clínico Universitario de Valencia
Valencia, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.